Jordi Remon: We had efficacy data on ADCs after osimertinib and PD in EGFR-mutant NSCLC

Jordi Remon, Cancer Specialist at CIOCC Barcelona, shared on X:

“We had efficacy data ADCs after osi-PD in EGFRm NSCLC. Today good mPFS (9.5-11.7) with Osi+DatopotamAb Dxd after osi-PD. Data looks promising than chemo+Amiv. Better protection maintaining osi? Biomarker for dato? Toxicity is imp. Future trial: osi-DATOD vs Ami-CT?”